Filter results

Clinical Studies

Open

  • A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901) Rochester, Minn.

    The overall goal of this study is the prospective evaluation of children with severe combined immunodeficiency and related disorders who are treated under a variety of protocols at multiple participating institutions. The study aims to identify variables contributing to the best outcomes for stem cell transplant as treatment for severe combined immunodeficiency disorder.

  • Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995 Rochester, Minn.

    Chronic granulomatous disease (CGD) is an inherited immune system abnormality in which bone marrow transplantation has been shown to be curative. However the risks of transplantation are high and not all patients with CGD may need to undergo this high risk procedure. The purpose of this study is to determine the long term medical condition and daily functioning of patients with CGD after a transplant and if possible, compare these results to patients who do not undergo a transplant.

  • Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COLCORONA) Jacksonville, Fla., Rochester, Minn. This is a phase 3, multi-center, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 infection and have at least one high-risk criterion. Approximately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo tablets for 30 days.
  • Genetic studies in Common Variable Immunodeficiency (CVID) Rochester, Minn.

    Common variable immunodeficiency (CVID) is a clinically, genetically and immunologically heterogeneous primary immunodeficiency disease (PID). The goal of this study is to perform whole exome sequencing (WES) to assess for monogenic defects that maybe be disease causing and may help in selection of appropriate therapeutic interventions including the possibility of  hemopoietic stem cell transplant (HSCT).

Contact Us for the Latest Status

  • Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COLCORONA) Scottsdale/Phoenix, Ariz. This is a phase 3, multi-center, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 infection and have at least one high-risk criterion. Approximately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo tablets for 30 days.
  • Innovating the Practice of Atopic Dermatitis (Eczema):Addressing the Metabolic Milieu to Prevent the Atopic March Rochester, Minn.

    The purpose of this study is to compare the assessment of the composition of the fecal, nasal,oral and skin microbiota in patients with AD (cases) as compared to age/sex and diet matched control children without atopic dermatitis, and to apply mass-spectrometry-based metabolomic approach to analyzing fecal, nasal, oral and skin samples from cases, in order to characterize their biochemical metabolic profiles by comparison with those of their controls.

  • NIH Participation to USIDNET Registry Rochester, Minn.

    The purpose of this study is to build a National Registry of individuals with one of the group of primary immune deficiency diseases. A "Registry" is a list of basic information about people who have a certain disease or condition in common. These immune deficiency diseases are thought to be rare and include: Severe combined immunodeficiency (SCID), leukocyte adhesion deficiency (LAD), X-linked Agammaglobulinemia (XLA), common variable immune deficiency (CVID), DiGeorge syndrome (DGS), Hyper IgM syndrome (HIGM), Wiskott Aldrich syndrome (WAS) and chronic granulomatous disease (CGD). We would like to contribute data on a number of subjects with these relatively rare diseases to this National Registry Data Base. The information will be age, sex, race or ethnic group, immunologic lab tests that were used to diagnose the condition, what complications may have occurred since the condition started, lung disease, blood changes, etc. and the results of various treatments used. The goal is to discover basic outcome data, ethnic, racial characteristics, kind of complications and useful treatments. You will not be contacted by anyone unless you authorize it. If a new study about you (or your child’s) immune defect comes up, your doctor will be notified, who can then share this with you to find out if you are interested in participating or not. Alternatively you may elect to be contacted directly by the Registry to determine your interest in participation.

Closed for Enrollment

  • Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904) Rochester, Minn.

    Wiskott - Aldrich syndrome (WAS) is a rare serious medical condition that causes problems both with the immune system and with easy bruising and bleeding. The immune abnormalities cause patients with WAS to be very susceptible to infections. Depending on the specific type of primary immune deficiency diseases, there are effective treatments, including antibiotics, cellular therapy and gene therapy, but studies of large numbers of patients are needed to determine the full range of causes, natural history, or the best methods of treatment for long term success. This multicenter study combines retrospective, prospective and cross-sectional analyses of the transplant experiences for patients with WAS who have already received Hematopoietic cell transplant (HCT) since 1990, or who will undergo HCT during the study period. The retrospective and prospective portions of the study will address the impact of a number of pre and post-transplant factors on post-transplant disease correction and ultimate benefit from HCT.  The cross-sectional portion of the study will assess the benefit of HCT 2 years post-HCT.

  • Fecal Microbiota and its Association with Food Allergies in Children Rochester, Minn.

    Our long term aim is identify unique microbiota associated with allergic disease, esp. food allergies and its association with allergic disease state (persistence of food allergies Vs. outgrowth of food allergies) which in turn will facilitate the use of probiotics to decrease the disease burden of allergic diseases.

  • Immunogenicity of PPSV-23 After PCV-13 Vaccination in Adult Asthmatic Patients Rochester, Minn.

    Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine if they are given Prevnar initially.

.